Please ensure Javascript is enabled for purposes of website accessibility

Why Verastem, Inc. Stock Is Crashing Today

By George Budwell - Sep 25, 2018 at 2:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The sell-off follows news of Verastem's first regulatory approval in oncology.

What happened

Shares of Verastem (VSTM 0.00%), a small-cap oncology company, fell as much as 21% on more than four times the stock's normal trading volume today.

The culprit? Verastem appears to be falling victim to the typical "sell the news" trend that accompanies so many biotechs following their first regulatory approval. On Monday, the company announced that the Food and Drug Administration (FDA) approved Copiktra (duvelisib) as a treatment for adult patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma after at least two prior therapies. This approval marks Verastem's entrance into the realm of commercial-stage biotechs.  

Cancer cell surrounded by red blood cells.

Image source: Getty Images.

As of 1:21 p.m. EDT, Verastem's shares were still down 14%.

So what

Before today's pullback, Verastem's stock was up by a monstrous 191% for the year, thanks to the growing optimism among investors that Copiktra would indeed be approved by the FDA. The flip side is that Verastam now has to contend with actually meeting analysts' quarterly sales projections for Copiktra -- a feat that few newly minted commercial biotechs achieve right off the bat. And that's probably a major reason why some investors are ringing the cash register today.

The FDA also tagged the drug's label with a box warning for four fatal or serious toxicities: infections, diarrhea or colitis, cutaneous reactions, and pneumonitis. But the more pressing issue weighing on the stock today is arguably Verastem's lack of experience when it comes to launching a drug. 

Now what

Verastem plans on making Copiktra available to patients immediately. That's the good news. The not-so-good news is that this drug is set to go head-to-head against a crowded field of competitors, including Bayer's Aliqopa and Gilead Sciences' Zydelig. That doesn't mean that Verastem can't carve out a profitable niche, but investors may need to be patient with Copiktra's commercial progress.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Verastem, Inc. Stock Quote
Verastem, Inc.
VSTM
$1.25 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.